Your session is about to expire
What is Invokamet
MetforminThe Generic name of this drug
Treatment SummaryMetformin is a medication used to treat type 2 diabetes. It is the most commonly prescribed drug for this condition and is used by more than 120 million people around the world. Metformin works by lowering blood sugar levels without causing hypoglycemia. It also helps reduce insulin resistance and fasting insulin levels, resulting in modest weight loss for some patients. Metformin was approved for use in Canada in 1972 and in the United States in 1995. It is available in both regular and extended-release forms.
Metformin Hydrochlorideis the brand name
Invokamet Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Metformin Hydrochloride
Metformin
2002
1263
Approved as Treatment by the FDA
Metformin, otherwise known as Metformin Hydrochloride, is approved by the FDA for 16 uses which include Congestive Heart Failure and Physical Activity .Congestive Heart Failure
Used to treat Heart Failure in combination with Dapagliflozin
Physical Activity
Used to treat Exercise in combination with Dapagliflozin
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin
Hospitalizations
Used to treat Hospitalizations in combination with Dapagliflozin
Diet
Used to treat Diet in combination with Dapagliflozin
Type 1 Diabetes
Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin
Chronic Kidney Disease
Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin
NYHA Functional Class II-IV Heart Failure
Used to treat NYHA Functional Class II-IV Heart Failure in combination with Dapagliflozin
Ejection fraction decreased
Used to treat Ejection fraction decreased in combination with Dapagliflozin
Diabetic Ketoacidosis
Used to treat Diabetic Ketoacidosis in combination with Saxagliptin
uncontrolled diabetes
Used to treat uncontrolled diabetes in combination with Rosiglitazone
Cardiovascular Disease
Used to treat Cardiovascular Risk in combination with Dapagliflozin
Cardiovascular Diseases
Used to treat established cardiovascular disease in combination with Dapagliflozin
decreased estimated glomerular filtration rate
Used to treat decreased estimated glomerular filtration rate in combination with Dapagliflozin
Cardiovascular Mortality
Used to treat Cardiovascular Mortality in combination with Dapagliflozin
Kidney Failure
Used to treat End Stage Renal Disease (ESRD) in combination with Dapagliflozin
Effectiveness
How Invokamet Affects PatientsInsulin is a hormone that helps control blood sugar levels, but in people with Type 2 diabetes this hormone is not working as it should. Metformin helps improve insulin's effectiveness by decreasing the amount of glucose made by the liver and reducing the amount of glucose that is absorbed by the intestines. It also helps the body use insulin better. In a study, people taking metformin had lower fasting plasma glucose levels (down 59 mg/dL) and lower glycosylated hemoglobin (HbA1c) levels (down 1.4%) than those taking a placebo.
How Invokamet works in the bodyMetformin works by decreasing the amount of glucose produced in your liver, decreasing how much glucose is absorbed from food, and increasing how sensitive your body is to insulin. It does this by blocking a specific protein in your liver which helps produce energy, triggering a chain reaction that ends with increased glucose metabolism in your intestines and decreased glucose production in your liver. Metformin also increases a hormone in your gut called glucagon-like peptide 1, which helps your body use glucose more efficiently. All these pathways combined work to lower blood glucose levels and control type II diabetes.
When to interrupt dosage
The advisable dose of Invokamet is contingent upon the diagnosed condition, such as Diet, inadequate response to metformin and Diabetic Ketoacidosis. The degree of dosage fluctuates as per the delivery approach (e.g. Oral or Tablet - Oral) featured in the table underneath.Condition
Dosage
Administration
decreased estimated glomerular filtration rate
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Diabetic Ketoacidosis
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Type 1 Diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Polycystic Ovarian Syndrome
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Congestive Heart Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Physical Activity
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Type 2 Diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Chronic Kidney Disease
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Kidney Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Diet
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Hospitalizations
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Cardiovascular Disease
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Cardiovascular Mortality
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
inadequate response to metformin
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Ejection fraction decreased
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
NYHA Functional Class II-IV Heart Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Cardiovascular Diseases
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
uncontrolled diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
diet and exercise not sufficient for diabetes control
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release - Oral, For suspension, extended release, Kit - Oral
Warnings
Invokamet ContraindicationsCondition
Risk Level
Notes
severe hepatic dysfunction
Do Not Combine
Impaired Renal Function
Do Not Combine
cardiovascular collapse
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Operative Surgery
Do Not Combine
Metabolic acidosis
Do Not Combine
cardiorespiratory insufficiency caused by Heart Failure
Do Not Combine
Impaired Renal Function
Do Not Combine
kidney function unknown
Do Not Combine
Hypovolemic Shock
Do Not Combine
serum creatinine above upper limit for age range
Do Not Combine
ethanol
Do Not Combine
Acute Coryza
Do Not Combine
Hypoxemia
Do Not Combine
Liver Failure
Do Not Combine
Lactic Acidosis
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Impaired Renal Function
Do Not Combine
estimated GFR <30mL/min
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Metformin may interact with Pulse Frequency
Common Invokamet Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Metformin.
Procainamide
Major
The excretion of Procainamide can be decreased when combined with Metformin.
Topotecan
Major
The excretion of Topotecan can be decreased when combined with Metformin.
Abacavir
Minor
Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Invokamet Toxicity & Overdose RiskThe toxic dose of metformin in rats is 1g/kg when taken orally, and 500mg/kg when given intraperitoneally. In mice, the toxic dose is 1450mg/kg when taken orally and 420mg/kg when given intraperitoneally. Metformin can decrease the body's ability to absorb lactate, which can lead to a dangerous build-up of lactic acid in the bloodstream (lactic acidosis). Symptoms of lactic acidosis include fatigue, muscle pain, abdominal pain, difficulty breathing, and drowsiness. Risk factors for lactic acidosis include kidney damage, use
Invokamet Novel Uses: Which Conditions Have a Clinical Trial Featuring Invokamet?
There are currently 346 active clinical trials analyzing the potential of Invokamet to target Type 2 Diabetes, Type 1 Diabetes and inadequate response to metformin therapies.Condition
Clinical Trials
Trial Phases
Type 1 Diabetes
145 Actively Recruiting
Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 2, Phase 4
inadequate response to metformin
0 Actively Recruiting
Cardiovascular Disease
30 Actively Recruiting
Not Applicable, Phase 1, Early Phase 1, Phase 3, Phase 2
Polycystic Ovarian Syndrome
9 Actively Recruiting
Phase 1, Not Applicable, Phase 2, Phase 3, Early Phase 1, Phase 4
Chronic Kidney Disease
114 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Type 2 Diabetes
193 Actively Recruiting
Phase 2, Not Applicable, Early Phase 1, Phase 1, Phase 4, Phase 3
Diabetic Ketoacidosis
3 Actively Recruiting
Phase 2, Early Phase 1, Not Applicable
decreased estimated glomerular filtration rate
0 Actively Recruiting
Kidney Failure
54 Actively Recruiting
Phase 3, Phase 1, Phase 2, Phase 4, Not Applicable
Congestive Heart Failure
312 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1, Phase 4
Diet
5 Actively Recruiting
Not Applicable
uncontrolled diabetes
0 Actively Recruiting
NYHA Functional Class II-IV Heart Failure
0 Actively Recruiting
Ejection fraction decreased
0 Actively Recruiting
Hospitalizations
2 Actively Recruiting
Not Applicable
Cardiovascular Diseases
0 Actively Recruiting
Physical Activity
39 Actively Recruiting
Not Applicable, Phase 2, Phase 1, Early Phase 1
Cardiovascular Mortality
0 Actively Recruiting
diet and exercise not sufficient for diabetes control
0 Actively Recruiting
Invokamet Reviews: What are patients saying about Invokamet?
5Patient Review
6/20/2016 This drug is excellent at controlling blood sugar. However, a side effect is weight loss. I went from 210 Lbs to 176 Lbs in two months.
4.7Patient Review
4/24/2018 I've lost 46 pounds since starting this treatment, and my A1C dropped from 12 to 8. I feel a lot better overall; the only problem is that my toes and fingers stay cold, but when rubbed they have good blood flow and will warm up.
4.7Patient Review
9/27/20154.3Patient Review
1/26/2017 My doctor put me on this medication, and after six months my A1C had risen from a 7 to almost a 10. In addition to making me very thirsty, I also had to urinate more frequently--particularly in the evening hours. Invokamet was not for me; the only good thing that came of it was that I lost about 15 pounds. Thankfully, I've since switched to Trajenta under my doctor's care and things are going much better.
4.3Patient Review
3/18/20163.7Patient Review
12/4/20141.7Patient Review
8/1/2016 I lost 20 pounds in the first four months, and I haven't experienced any negative side effects so far.
Patient Q&A Section about invokamet
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is the difference between Invokana and Invokamet?
"The medicine works to remove sugar from the body by causing the sugar to be passed through urine. The medicine is called Invokana when it is taken as a single medicine. When the medicine is combined with the diabetes drug metformin, it is called Invokamet."
Answered by AI
What is Invokamet used for?
"INVOKAMET and INVOKAMET XR can be used to lower blood sugar (glucose), reduce the risk of major cardiovascular events, and improve glycemic control in adults with type 2 diabetes."
Answered by AI
What type of drug is Invokamet?
"Invokamet is a combination medication containing canagliflozin and metformin. Both of these medications work together to lower blood sugar levels in adults with type 2 diabetes."
Answered by AI
Is Invokamet the same as metformin?
"Invokana is not the same as metformin. They are both medicines that lower blood sugar levels, but they work in different ways."
Answered by AI